Dr. Deborah Doroshow, MD, PhD
Claim this profileMount Sinai Hospital
Studies Tumors
Studies Solid Tumors
13 reported clinical trials
37 drugs studied
Area of expertise
1Tumors
Stage IV
Stage III
PTEN negative
2Solid Tumors
Stage IV
Stage III
PTEN negative
Affiliated Hospitals
Clinical Trials Deborah Doroshow, MD, PhD is currently running
Pembrolizumab
for Advanced Non-Small Cell Lung Cancer
This single center open-label trial will enroll a single cohort of patients with advanced non-small cell lung cancer (NSCLC) who are ineligible for treatment with curative intent due to 1) disease stage IV, or 2) inability to tolerate intensive surgery or chemo-radiation. Patients will be eligible for the trial if ISMMS reviewed samples from tumor biopsy have a PDL-1 TPS ≥ 1% and have ECOG performance status rated 2 or 3. All patients will receive anti PD-1 therapy with pembrolizumab 200mg IV every 3 weeks, during which patients will also undergo serial QOL assessments. This trial will follow a phase II single arm, open label design. The study will enroll 45 patients evaluable for the primary endpoint of which will be change in QOL as measured by the EORTC's QLQ-C30 between Day 1 and Day 84 +/- 7 days. Secondary outcomes including evaluation for development of confounding mental health conditions will be evaluated via serial HADS assessments. Concomitant radiographic assessment with PET/CT, regardless of the doses of pembrolizumab received, will allow for evaluation of secondary efficacy outcomes, including disease response by RECIST 1.1 criteria.
Recruiting1 award Phase 215 criteria
Ipatasertib + Chemotherapy
for Cancer
This phase II ComboMATCH treatment trial tests the usual treatment of chemotherapy (paclitaxel) plus ipatasertib in patients with solid tumor cancers that that cannot be removed by surgery (unresectable), has spread to nearby tissue or lymph nodes (locally advanced) or from where it first started (primary site) to other places in the body (metastatic), and has an AKT genetic change. Chemotherapy drugs, such as paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Targeted therapy, such as Ipatasertib, may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. The addition of ipatasertib to paclitaxel in solid tumors with an AKT genetic change could increase the percentage of tumors that shrink as well as lengthen the time that the tumors remain stable (without progression). Researchers hope to learn if paclitaxel plus ipatasertib will shrink this type of cancer or stop its growth.
Recruiting1 award Phase 2
More about Deborah Doroshow, MD, PhD
Clinical Trial Related4 years of experience running clinical trials · Led 13 trials as a Principal Investigator · 7 Active Clinical TrialsTreatments Deborah Doroshow, MD, PhD has experience with
- Paclitaxel
- Pembrolizumab
- Atezolizumab
- Ipatasertib
- Binimetinib
- Palbociclib
Breakdown of trials Deborah Doroshow, MD, PhD has run
Tumors
Solid Tumors
Cancer
Non-Small Cell Lung Cancer
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Deborah Doroshow, MD, PhD specialize in?
Deborah Doroshow, MD, PhD focuses on Tumors and Solid Tumors. In particular, much of their work with Tumors has involved Stage IV patients, or patients who are Stage III.
Is Deborah Doroshow, MD, PhD currently recruiting for clinical trials?
Yes, Deborah Doroshow, MD, PhD is currently recruiting for 7 clinical trials in New York New York. If you're interested in participating, you should apply.
Are there any treatments that Deborah Doroshow, MD, PhD has studied deeply?
Yes, Deborah Doroshow, MD, PhD has studied treatments such as Paclitaxel, Pembrolizumab, Atezolizumab.
What is the best way to schedule an appointment with Deborah Doroshow, MD, PhD?
Apply for one of the trials that Deborah Doroshow, MD, PhD is conducting.
What is the office address of Deborah Doroshow, MD, PhD?
The office of Deborah Doroshow, MD, PhD is located at: Mount Sinai Hospital, New York, New York 10029 United States. This is the address for their practice at the Mount Sinai Hospital.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.